Unity Looks Ahead To Pivotal Study With Positive DME Data For UBX1325
Executive Summary
The company announced 24-week results from the Phase II BEHOLD trial in diabetic macular edema patients already treated with anti-VEGF therapy, showing gains in a tough population.
You may also be interested in...
Longer-Term DME Data Bolster Optimism Around Mechanism For Unity’s UBX1325
The company announced 48-week, Phase IIa data for the drug in diabetic macular edema, an update from 24-week data the company announced in November.
Unity’s UBX1325 Faces Uncertain Path Forward In AMD, But DME Still Looks Promising
The company said the Phase II ENVISION study of the drug in wet age-related macular degeneration did not show non-inferiority to Eylea, leaving it with an uncertain path forward in that indication.
Financing Available For Some, But Not All Biopharma Companies In 2023
Investors, advisors and CEOs at the J.P. Morgan Healthcare Conference and Biotech Showcase were somewhat optimistic about fundraising this year, but noted certain companies may have to call it quits.